Low Dose Naltrexone (LDN) as a Cancer Adjunct: Mechanisms, Evidence, and Clinical Protocol
How LDN modulates OGF/OGFr signaling, upregulates NK cell activity, and may reduce tumor growth—with dosing protocols and candidate selection criteria.
Clinical Protocols
Integrative Oncology
Low Dose Naltrexone (LDN) as a Cancer Adjunct: Mechanisms, Evidence, and Clinical Protocol.
01
02
High-Dose IV Vitamin C: Evidence, Protocol, and Clinical Applications
Dr. med. univ. Julian Douwes reviews high-dose IV vitamin C: mechanisms, dosing protocols, cancer adjunct use, immune support, and safety considerations from clinical practice.
03
Hyperthermia Treatment for Cancer: What the Evidence Shows
How hyperthermia cancer treatment works, evidence levels, clinical experience at St. George Hospital, types, and what patients should expect. Written by a physician.
